Polypsychopharmacy: A frequent and debatable practice in psychiatric inpatients [9]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 510-512

  De Las Cuevas, Carlos ^a   Sanz, Emilio ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; LITHIUM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUVANT THERAPY; ADULT; AGED; DRUG EFFICACY; DRUG USE; FEMALE; HOSPITAL PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES;

EID: 25444494508     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000177847.77791.99     Document Type: Letter

References (15)

1. de las Cuevas C, Sanz EJ, de la Fuente JA. Variations in antidepressant prescribing practice: clinical need or market influences? Pharmacoepidemiol Drug Saf. September 2002;11(6):515-522.
2. de las Cuevas C, Sanz E. Do therapeutic indications of antidepressants change from one year to another? Pharmacoepidemiol Drug Saf. May 2004;13(5):309-314.
3. Harris CM, Heywood PL, Clayden AD. The Analysis of Prescribing in General Practice A Guide to Audit and Research. London: HMSO; 1990.
4. Murray MD, Kroenke K. Polypharmacy and medication adherence: small steps on a long road. J Gen Intern Med. February 2001;16(2):137-139.
5. Sealy P, Whitehead PC. Forty years of deinstitutionalization of psychiatric services in Canada: an empirical assessment. Can J Psychiatry. April 2004;49(4):249-257.
6. Christensen RC. The ethics of cost shifting in community psychiatry. Psychiatr Serv. August 2002;53(8):921.
7. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: rational and irrational polypharmacy. Psychiatr Serv. August 2001;52(8):1033-1036.
8. NASMHPD Medical Directors, NASMHPD Medical Directors' Technical Report on Psychiatric Polypharmacy. September 10, 2001; Alexandria, Virginia.
9. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. February 2002;63(2):93-94.
10. Kendell R, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry. January 2003;160(1):4-12.
11. de las Cuevas C, Sanz EJ. Polypharmacy in psychiatric practice in the Canary Islands. BMC Psychiatry. July 5, 2004;4(1):18.
12. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr Scand. November 2002;106(5):321-322.
13. Magliano L, Fiorillo A, Guarneri M, et al. Prescription of psychotropic drugs to patients with schizophrenia: an Italian national survey. Eur J Clin Pharmacol. September 2004;60(7):513-522.
14. Lelliot P, Paton C, Harrington M, et al. The influence of patients variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for inpatients. Psychiatr Bull. 2002;(26):411-414.
15. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. January 2003;54(1):55-59.